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1  | INTRODUC TION
Cancer continues to be a leading cause of death and the most crucial hurdle 
to extend life expectancy in the current century (Bray et al., 2018). In spite 
of the substantial advancement in cancer research over the last decades, 
anti-cancer approaches remain largely ineffective and long-term survival 
continues to be disappointing in many solid tumours (Apolone, Joppi, 
Bertele', & Garattini, 2005). Oral squamous cell carcinoma (OSCC) is the 
most common oral malignancy, which accounts for about 90% of all ma-
lignant neoplasms of the oral cavity (Johnson, Jayasekara, & Amarasinghe, 
2011). It has been documented that OSCC may develop from pre-existing 
chronic oral inflammatory conditions, and other potentially premalignant 
disorders, such as lichen planus, lichenoid reaction, leukoplakia and eryth-
roplakia (Speight, Khurram, & Kujan, 2018). Unfortunately, OSCC has an 
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Abstract
Oral squamous cell carcinoma (OSCC), the most common oral malignancy, shows an 
increasing rate of incidence worldwide. In spite of the recent advances in cancer re-
search, OSCC therapy continues to have unfavourable outcomes, and thus, patient's 
prognosis remains relatively poor. Current research has been devoted to identify-
ing novel therapeutic targets also in the tumour microenvironment (TME). Histamine 
and its G-protein-coupled receptors (H1R-H4R) play vital roles in multiple cancer-
associated processes in TME, where histamine is mainly produced by mast cells. 
However, oral epithelial cells were recently shown to produce low concentrations 
of histamine in autocrine and paracrine modes. These findings, together with the 
discovery of the high-affinity histamine H4 receptor, have led to a massive increase 
in our understanding of histamine functions. In this review, we aim to summarize the 
most recent findings regarding histamine and its receptors and their involvement in 
oral carcinogenesis—from oral potentially malignant disorders (OPMDs) to invasive 
OSCC. Importantly, histamine receptors are differentially expressed in OPMDs and 
OSCC. Furthermore, H1R and H4R are associated with clinicopathological character-
istics of OSCC patients, suggesting a role in prognosis. Due to the enormous success 
of histamine-based medications, histamine receptors may also represent promising 
and viable drug targets in oral cancer.
K E Y W O R D S
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unfavourable prognosis with the 5-year overall survival is stagnant at 
around 50% (Sim, Hwang, & Ahn, 2019). In addition, OSCC therapy can 
provoke detrimental effects in patients, including impairment of vital 
functions, severe toxicity and poor responses (Lo Nigro, Denaro, Merlotti, 
& Merlano, 2017; Rivera, 2015). In order to overcome such challenges, 
recent research has been devoted to identifying and targeting novel 
“druggable” components of the tumour microenvironment (TME) (Roma-
Rodrigues, Mendes, Baptista, & Fernandes, 2019). Indeed, a better un-
derstanding of cancer biology as well as the interactions between various 
components of TME is imperative to discover novel anti-cancer drugs 
with an improved efficacy and reduced side effects.
Histamine is one of the most studied substances in medicine, and 
it has long been suggested as a crucial player in tumorigenesis (Medina 
et al., 2013). Histamine regulates a wide variety of physiological and 
pathological processes including neurotransmission, allergic reactions 
and inflammatory responses to foreign pathogens (Panula et al., 2015). 
In addition, histamine influences numerous carcinogenesis-associ-
ated events such as cell division, proliferation and apoptosis (Chen & 
Hu, 2018; Cricco et al., 2006; Jakhar, Paul, Bhardwaj, & Kang, 2016). 
Furthermore, most cancer cells and in vitro tumour models contain 
considerable amounts of endogenous histamine, which signify its role 
as a crucial player in cancer (Massari, Nicoud, & Medina, 2020). The 
involvement of histamine and histamine receptors in different types 
of cancer has been extensively summarized in several comprehensive 
reviews (Kennedy, Hodges, Meng, Alpini, & Francis, 2012; Massari 
et al., 2020; Nicoud, Formoso, & Medina, 2019). However, in this mini-
review, we aim to focus on the current knowledge regarding histamine 
and histamine receptors and their potential role in oral carcinogenesis.
2  | HISTAMINE SYNTHESIS AND 
DEGR ADATION
Histamine [2-(4-imidazolyl)-ethylamine] is a short-acting biogenic 
amine that is synthesized from the essential amino acid histidine via 
the catalytic enzyme L-histidine decarboxylase (HDC). Histamine is 
ubiquitously distributed throughout the body with higher concen-
trations in the skin and gastrointestinal tract (Panula et al., 2015). 
It is released into the extracellular milieu and produces its actions 
through autocrine and paracrine mechanisms (Thangam et al., 2018). 
The typical cellular sources of histamine in the body are the pluri-
potent mast cell (MC), gastric enterochromaffin-like cells, the hista-
minergic neurons and basophils (Tiligada & Ennis, 2020). These cells 
synthesize and store copious amounts of histamine and represent 
the major or “professional” histamine-producing cells (Huang, Li, 
Liang, & Finkelman, 2018; Konttinen et al., 2013). In addition, other 
cell types were reported to synthesize and release about 1000-fold 
less quantities of histamine and hence named “non-professional” 
histamine-producing cells, including T-lymphocytes, dendritic cells 
and oral epithelial cells (Salem, Rozov, et al., 2017). Professional 
histamine-producing cells, such as MCs, secrete histamine by active 
exocytosis in a burst-like manner following activation by stimulants. 
In contrast, non-professional histamine-producing cells release his-
tamine passively along its concentration gradient through organic 
cation transporters (OCTs) such as OCT3 (Ogasawara et al., 2006) 
(Table 1).
To terminate its effects, histamine concentration in the intra- 
and extracellular spaces should be regulated by an efficiently con-
trolled enzymatic degradation system. Histamine degradation 
is carried out either by diamine oxidase (DAO) or by histamine 
N-methyltransferase (HNMT), which both exhibit distinct functions 
and localization patterns (Darvas et al., 2003). The latter cytosolic 
enzyme, HNMT, degrades the intracellular histamine via ring meth-
ylation, while DAO degrades extracellular histamine via oxidative 
deamination (Smolinska, Jutel, Crameri, & O'Mahony, 2014).
3  | HISTAMINE RECEPTORS
Histamine exerts its effects via four distinct G-protein-coupled re-
ceptors: histamine H1R through histamine H4 receptor (H1R-H4R), 
which contain three domains—extracellular, transmembranous and 
TA B L E  1   Main differences between professional and non-professional histamine-producing cellsa
Feature Professional cells Non-professional cells
Main cell types Mast cells, basophils and histaminergic neurons Tumour cells, dendritic cells, 
lymphocytes and epithelial cells
Histamine-synthesizing enzyme Short-length HDC (53 KD) Full-length HDC (74 KD)
Histamine synthesis rate Fast and efficient Slow (~1,000 times slower)
Histamine storage Yes (in secretory granules) No
Amount of released histamine High (micromolar) Low (nanomolar or less)
Mode of histamine release Active (require stimulus) Passive (concentration gradient)
Main functional receptors Low-affinity (H1R, H2R) High-affinity (H3R, H4R)
Time range of the effect Short-term Long-term
Spatial range Pathological “hotspots” Pathophysiological
Abbreviations: DAO, diamine oxidase; HDC, L-histidine decarboxylase; HNMT, histamine N-methyltransferase; KD, kilodalton.
aModified from Konttinen et al., 2013. 
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intracellular. The first discovered receptor subtype of histamine, 
H1R, is mainly localized on the vascular endothelial and smooth 
muscle cells. Histamine stimulates H1R through Gαq/11, which in 
turn activates phospholipase C and elevates intracellular Ca++ lev-
els. Consequently, this results in the contraction of smooth muscles, 
increases vascular permeability and induces the production of pros-
tacyclin and platelet-activating factor (Panula et al., 2015; Thangam 
et al., 2018).
The first generation of H1R-based anti-histamines has led to the 
production of very successful medications. However, scientists no-
ticed that certain histamine-driven effects were not managed by H1 
antagonists and thus the second receptor subtype, H2R, was char-
acterized. The H2R is Gαs-coupled receptor, which upon activation 
can induce mucus production and secretion of gastric acid (Thangam 
et al., 2018). As it is mainly expressed on the parietal cells, antago-
nizing H2R (via H2-blockers) has revolutionized the management of 
gastric and duodenal ulcerations by inhibiting the production of hy-
drochloric acid (Konttinen et al., 2013). In addition, H2R was found in 
some immune cells, such as neutrophils and eosinophils. In this con-
text, targeting H2R seems to support Th2-mediated effects and to 
counteract Th1-type inflammatory response (Akdis & Simons, 2006). 
Based on pharmacological evidence, the detection of the third hista-
mine receptor, H3R, in 1983 indicated a profound influence of hista-
mine on various neurotransmitter balances (Panula et al., 2015). The 
H3R is coupled to the Gαi/o and it is almost exclusively expressed in 
neurons, and thus, blocking ligands are researched as therapeutic 
targets in CNS disorders (Massari et al., 2020).
At the turn of the millennium, the newest histamine receptor, 
H4R, was characterized independently by different research groups 
(Panula et al., 2015). The H4R is a Gαi/o-coupled receptor and it shares 
a 37% homology with H3R, but unlike H3R, it is predominantly ex-
pressed in cells of the immune system such as MCs, T-lymphocytes 
and natural killer cells (Nicoud et al., 2019; Thurmond, 2015; van 
Rijn et al., 2008). Indeed, the identification of potent ligands for 
H4R (agonists, neutral antagonists and inverse agonists) has re-
vealed its immunomodulatory role in inflammatory responses and 
in cancer (Medina et al., 2013; Thurmond et al., 2008). Interestingly, 
activation of H4R resulted in immune cell chemotaxis in MCs, eo-
sinophils, dendritic cells and regulatory T cells. For instance, acti-
vation of H4R by a selective agonist (4-methylhistaminet) induced 
the expression and release of various pro-inflammatory cytokines 
and chemokines such as transforming growth factor beta-1, tumour 
necrosis factor alpha and beta, and macrophage colony-stimulating 
factor, in addition to many interleukins (e.g. IL-8, IL-6, IL-16, IL-3, IL-
10) in human MCs. Furthermore, targeting H4R with another selec-
tive agonist (clobenpropit) resulted in a concentration-dependent 
release of IL-16 from cytotoxic T cells. Importantly, H4R exhibits a 
differential expression in various primary neoplasms compared with 
normal tissues, such as oesophageal, gastric, colorectal and breast 
cancers, which indicates a possible involvement in carcinogenesis 
(Jemima, Prema, & Thangam, 2014; Nicoud et al., 2019; Panula 
et al., 2015). The main features of histamine receptor subtypes are 
summarized in Table 2.
4  | CONCENTR ATION-DEPENDENT 
AC TION OF HISTAMINE
Although histamine has been exploited in medicine since 1930s, li-
gands targeting H1R-H3R remain, by and large, ineffective in treating 
many immune-associated diseases and cancer. In fact, such limitation 
has been attributed to the substantial variations in the extracellular 
levels of histamine in different body tissues (Konttinen et al., 2013; 
Panula et al., 2015). Extracellular histamine can be too low to induce 
signalling cascade through the low-affinity receptors, H1R and H2R 
(pKi = 4.3; 4.2, respectively), but already high enough to activate the 
high-affinity receptors, H3R and H4R (pKi = 8.0; 8.3, respectively) 
(Konttinen et al., 2013; Lim et al., 2005; Thurmond et al., 2008). This 
indicates that low concentrations of histamine can mediate numer-
ous unidentified effects in immune cells through the H4R (Konttinen 
et al., 2013). Therefore, the local level of histamine and the differ-
ential expression of its receptors are considered important factors 
in determining the biological response (Panula et al., 2015; Salem, 
Rozov, et al., 2017).
This is particularly important in terms of the recent identification 
of non-professional histamine-producing cells and their role in medi-
ating crucial pathophysiological processes (Konttinen et al., 2013). In 
this context, low levels of histamine, produced by non-professional 
histamine-producing cell, may sustain long-term oxidative stress in-
jury and thus induce progressive disorders including tumorigenesis 
and angiogenesis (Khatami, 2016). Emerging evidence suggests that 
ligands targeting H4R, in part because of its high affinity, may pro-
vide new drug targets to the therapy of chronic oral inflammatory le-
sions and cancer (Salem et al., 2019). For instance, activation of H4R 
by nanomolar agonist interfered with apoptosis and reduced cleav-
age of the early-apoptotic marker, poly (ADP-ribose) polymerase, in 
cultured salivary gland cells (Stegajev et al., 2014).
5  | INVOLVEMENT OF HISTAMINE 
IN OR AL POTENTIALLY MALIGNANT 
DISORDERS
Numerous lesions are associated with an increased risk of developing 
oral squamous cell carcinoma (OSCC), and hence, they were termed 
oral potentially malignant disorders (OPMDs) (Speight et al., 2018). 
Such lesions include, for instance, leukoplakia, erythroplakia, sub-
mucous fibrosis, oral lichen planus (OLP), lichenoid reactions and 
proliferative verrucous leukoplakia (Salem et al., 2018, Speight 
et al., 2018). There are many factors associated with the higher risk 
of malignant transformation, such as lesional site; tobacco and alco-
hol abuse, and detection of epithelial dysplasia (Speight et al., 2007, 
2018). In spite of the ongoing efforts, there is no clear clinical suc-
cess of any specific intervention in the treatment of OPMDS (Speight 
et al., 2018). The involvement of histamine and histamine receptors 
in OPMDs is summarized in Figure 1.
The pluripotent MC plays a crucial role in the development and 
perpetuation of many OPMDs by releasing potent pro-inflammatory 
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mediators such as histamine, cytokines and chemokines (Michailidou, 
Markopoulos, & Antoniades, 2008; Salem et al., 2019). In this re-
gard, the number of degranulated MCs was doubled in leukoplakia, 
oral submucous fibrosis and OLP, in an immediate vicinity of the le-
sional epithelium, compared with normal oral mucosa (Ankle, Kale, 
& Nayak, 2007; Salem et al., 2015). Similarly, an increased MC count 
was also observed in the lamina propria of oral epithelial dysplasia 
(Salem, Almahmoudi, et al., 2017).
Oral epithelial cells can synthesize and release low levels of 
histamine (Salem, Rozov, et al., 2017). Interestingly, histamine 
metabolism and transport are deranged in OLP lesions. Of note, 
histamine-synthesizing and transporting molecules (i.e. HDC and 
OCT3, respectively) were strongly increased while HNMT was de-
creased in OLP (Salem, Rozov, et al., 2017). Consequently, this could 
result in an accumulation of surplus histamine in the lesional epithe-
lium and sustain long-term oxidative stress. In addition, surplus his-
tamine can over time deteriorate the epithelial basement membrane 
by downregulating integrins and other important cellular adhesion 
molecules (Salem, Rozov, et al., 2017). Eventually, such persistent 
low-grade changes may perpetuate the inflammatory response and 
facilitate the potential tumorigenesis in OLP (Salem et al., 2019; 
Salem, Rozov, et al., 2017).
TA B L E  2   Main characteristics of histamine receptor subtypes
H1R H2R H3R H4R
Identification 1937 1972 1983 2000
Gene cloning 1993 1991 1999 2000
Amino acids 487 359 445 390
G-protein 
coupling
Gαq/11 Gαs Gαi/o Gαi/o
HA affinity (pKi) 4.2 4.3 7.8 8.3
HA activation Requires high HA levels Requires high HA levels Respond to ~1,000 times 
less HA




Wide; mainly in lung, blood 
vessels
Wide; mainly in stomach, 
heart
Neurons; central nervous 
system
Bone marrow; immune cells
Main effects Bronchoconstriction; 
vasodilatation
Gastric acid secretion Sleep-wake regulation Immune responses




Inflammatory lesions and 
cancer
Relevance to oral 
cancer
Yes; correlated with poorer 
DFS rates in OSCC patients
Yes; enhanced anti-cancer 
therapy in OSCC models
No evidence Yes; associated with the 
histopathologic grade of 
OTSCC
Abbreviations: DFS, disease-free survival; HA, histamine; OSCC, oral squamous cell carcinoma; OTSCC, oral tongue squamous cell carcinoma.
F I G U R E  1   Role of histamine and histamine receptors in oral carcinogenesis. (a) Normal oral keratinocytes express H1R, H2R and H4R. In 
addition, these cells can synthesize and release low levels of histamine. (b) In oral potentially malignant disorders (OPMD), such as oral lichen 
planus (OLP), mast cell (MC) count is noticeably increased in the lamina propria. Moreover, histamine metabolism is deranged in OLP, which 
leads to increased surplus histamine levels, upregulation of H1R and downregulation of the high-affinity H4R. Consequently, loss of H4R can 
affect the maintenance of oral epithelium and perpetuate the inflammatory response. On the other hand, histamine induces beta-defensin 
2 (BD-2) synthesis and release from keratinocytes, which seems to be regulated in part by H4R. (c) In oral squamous cell carcinoma (OSCC), 
the number of tumour-associated MC is also increased, which may trigger an “angiogenic switch” and induce further tissue degradation. 
Histamine regulates the expression of certain OSCC-associated oncogenes in oral keratinocytes. Furthermore, in OSCC, both H1R and H2R 
are upregulated while H4R is strongly diminished
(a) (b) (c)
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Histamine seems to regulate the epithelial-driven antimicrobial 
response in OLP (Salem et al., 2019). MC-derived histamine is able 
to stimulate the synthesis and release of the antimicrobial peptide, 
beta-defensin 2 (BD2), from oral epithelial cells (Kanda & Watanabe, 
2007). In turn, BD2 induces Ca++ mobilization and subsequent de-
granulation of MCs via Mas-related gene X2, which leads to fur-
ther production of histamine and BD2 (Subramanian et al., 2013). 
Importantly, activation of H4R showed regulatory effects on lipo-
polysaccharide-induced BD2 expression in cultured oral epithelial 
cells (Salem et al., 2019).
The immunoreactivity of H4R in oral epithelial cells was negatively 
correlated with MC count in OLP and epithelial dysplastic lesions 
(Salem, Almahmoudi, et al., 2017). In these lesions, H4R staining was 
markedly decreased and shifted towards upper epithelial cell layers, 
possibly as a result of the burst-released histamine from MCs. In agree-
ment with this, higher micromolar concentrations of histamine strongly 
downregulated the H4R transcript in vitro oral epithelial cells (Salem 
et al., 2015). On contrary, the H1R was strongly induced in OLP le-
sions, and the pattern was consistently distributed throughout the oral 
epithelial layers (Salem et al., 2019). Overall, and based on the current 
research findings, H4R seems to play an important role in the mainte-
nance of normal oral epithelium, which is disturbed in some prema-
lignant lesions due to an increased histamine production followed by 
H4R downregulation and H1R upregulation (Figure 1).
6  | INVOLVEMENT OF HISTAMINE IN 
OR AL C ANCER
Persistent potent responses in TME, mediated by variety of cells and 
substances, including MCs and histamine, are involved in promot-
ing cancer development and invasion (Marichal, Tsai, & Galli, 2013; 
Multhoff et al., 2012). Such profound procancerous effects of 
tumour-associated MCs include angiogenesis, tissue degrada-
tion, mediating cell interaction and remodelling of TME (Marichal 
et al., 2013).
Histamine and histamine receptors exhibit deranged expression 
in numerous types of cancer (Massari et al., 2020). In OSCC, Grimm 
et al. showed that H1R was expressed in OSCC cell lines BICR56 
and BICR3. Moreover, H1R status was correlated with a significantly 
poor disease-free survival in OSCC patients signifying the role of 
H1R signalling in OSCC (Grimm et al., 2013). In another study, H2R 
expression was induced in OSCC tissue compared with the adja-
cent normal tissue in hamster model of oral cancer (Parihar, Dube, 
& Gupta, 2013). It was also interesting that coupling of histamine 
to chlorin p6 enhanced the efficacy of photodynamic therapy and 
resulted in complete regression of large OSCC tumours (Parihar 
et al., 2013). Furthermore, administration of low concentrations of 
histamine reduced the boron neutron capture therapy-associated 
mucositis in hamster OSCC without jeopardizing the therapeutic ef-
fects (Monti Hughes et al., 2015).
Oral epithelial cells revealed a uniform pattern of H4R stain-
ing, which was strongly diminished in mobile tongue SCC (Salem, 
Almahmoudi, et al., 2017; Salem et al., 2015). Interestingly, such 
staining pattern was negatively associated with the histopatholog-
ical grade of OSCC specimens. Thus, samples with a higher OSCC 
grade had a higher MC count and a substantially lower H4R immu-
noreactivity (Salem, Almahmoudi, et al., 2017). These findings were 
also supported by in vitro cell culture findings. HDC and H4R were 
downregulated in the aggressive HSC-3 and SCC-25 mobile tongue 
SCC cells compared with the normal oral epithelial cells (Salem, 
Almahmoudi, et al., 2017).
The OSCC-associated MCs were observed mainly at the lam-
ina propria surrounding the tumour invasive front (Almahmoudi 
et al., 2018; Salem, Almahmoudi, et al., 2017). Increased MC 
count was also seen in hotspot microvascular density (MVD) 
areas (Michailidou et al., 2008; Salem, Almahmoudi, et al., 2017). 
Michailidou et al. concluded that during the progression from normal 
epithelium to invasive OSCC, both MC and MVD counts are signifi-
cantly increased and thus they might promote oral carcinogenesis 
(Michailidou et al., 2008). In fact, MCs induce neovascularization 
by releasing a wide variety of proangiogenic factors, such as vas-
cular endothelial growth factor, tryptase, IL-8 and histamine (Gaje 
et al., 2016). Supernatants obtained from degranulated in vitro MCs 
regulated the expression of several oral oncogenes, such as epider-
mal growth factor (EGF), EGF receptor and anti-apoptotic genes. 
Furthermore, histamine downregulated B-cell lymphoma 2 (Bcl-2) 
expression in cultured oral epithelial cells (Salem, Almahmoudi, et al., 
2017). Based on the aforementioned evidence, the weakened ex-
pression of H4R together with the induced levels of H1R/H2R and 
tumour-associated MCs seem to play crucial roles in promoting oral 
carcinogenesis (Figure 1). The infiltration of MCs into developing 
OSCC can also trigger an “angiogenic switch” that enhances neovas-
cularization in the developing tumour.
7  | CONCLUDING REMARKS
According to the GLOBOCAN 2018 estimates, cancer incidence 
and mortality are swiftly increasing worldwide (Bray et al., 2018). 
Hence, there is an urgent need to identify and validate new cancer-
relevant targets. Undoubtedly, there is an immense amount of data 
that signifies the role of histamine receptors in cancer initiation, 
progression and invasion (Massari et al., 2020). In particular, the 
discovery of the high-affinity H4R and its immunomodulatory ef-
fects has paved the way for novel perspectives in cancer research 
(Nicoud et al., 2019). Nevertheless, further mechanistic studies 
in preclinical models are needed to better elucidate the complex 
pathways triggered by histamine signalling in TME. Recently, much 
of interest has been revived in histamine as a promising therapeu-
tic approach in cancer patients. For instance, an immunotherapy 
with histamine dihydrochloride combined with low-dose IL-2 
significantly decreased the relapse rate in phase III clinical trial 
of acute myeloid leukaemia patients (Kiffin et al., 2018). Due to 
the enormous pharmacological success of ligands targeting hista-
mine receptors, this review encourages further research to better 
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understand the role of histamine signalling and whether it repre-
sents a viable drug target in oral cancer.
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